Xcout Intelatai Life Sciences
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
Subscribe to see atai Life Sciences’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
atai Life Sciences at a glance
atai Life Sciences is a biotech company headquartered in Germany. Its most recent funding round raised $157M in March 2021.
atai Life Sciences funding rounds
The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $157M | 8 named | |
| SEC Form D filing | $18.1M | — | |
| Series B | $24M | 4 named | |
| SEC Form D filing | $10.9M | — | |
| SEC Form D filing | $30.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent atai Life Sciences news
Investors
atai Life Sciences competitors
A few of atai Life Sciences's closest competitors — see the full list of competitors and alternatives →
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Reunion Neuroscience is a clinical-stage biopharmaceutical company that develops innovative therapeutics for underserved mental health disorders. Its lead drug candidate, luvesilocin, is a proprietary 5-HT2A agonist designed to provide durable antidepressant effects for patients with mood and anxiety disorders.
Intra-Cellular Therapies was a U.S. biopharmaceutical company focused on developing treatments for central nervous system disorders. Its principal product, CAPLYTA (lumateperone), is used to treat schizophrenia and depressive episodes associated with bipolar disorder in adults, serving patients and mental-healthcare providers.
Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Get atai Life Sciences's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on atai Life Sciences in Xcout Intel
- 7 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access